<DOC>
	<DOCNO>NCT02982187</DOCNO>
	<brief_summary>This randomize , multi-centre , open-label , placebo-device , cross-over study , 2x2 complete block design subject chronic obstructive pulmonary disease ( COPD ) ass benefit deliver triple therapy use single ELLIPTA dry powder inhaler ( DPI ) ( closed triple therapy ) versus deliver triple therapy use two different type DPI ( open triple therapy ) . The primary objective study evaluate proportion COPD subject make critical error use single ELLIPTA DPI versus use combination DISKUS® HANDIHALER® , TURBUHALER® HANDIHALER . At Visit 1 , subject demonstrate use ELLIPTA DPI , HANDIHALER DPI combination either DISKUS DPI ( sub-study 1 ) TURBUHALER DPI ( sub-study 2 ) , base treatment sequence . At end Visit 1 , subject complete inhaler preference questionnaire ( PQ ) . There active treatment subject continue take prescribed COPD medication duration study . ELLIPTA DISKUS register trademark GSK group company ; TURBUHALER register trademark AstraZeneca HANDIHALER register trademark Boehringer Ingelheim Pharma GmbH &amp; Co. KG .</brief_summary>
	<brief_title>A Clinical Study Assessing Critical Errors , Training/Teaching Time , Preference Attributes ELLIPTA® Dry Powder Inhaler , Comparison Combinations Dry Powder Inhalers Used Provide Triple Therapy , Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion Criteria Age &gt; =40 year Visit 1 Diagnosis COPD document history COPD , accordance definition European Respiratory Society . Current COPD Therapy : Currently receive maintenance therapy fix dose combination longacting beta 2agonist ( LABA ) inhale corticosteroid ( ICS ) . Subject may also receive longacting muscarinic antagonist ( LAMA ; also know longacting anticholinergic ) . Subjects must able continue use currently prescribe COPD maintenance inhaler therapy throughout study need short act betaadrenergic agonist ( SABA ) and/or short act muscarinic antagonist ( SAMA ) rescue use . Has current maintenance ICS/LABA COPD treatment least 4 week prior V0 evaluate unlikely change treatment within 4 week Visit 1 . Current former ( defined subject quit smoke least 3 month prior V0/V1 ) cigarette smoker &gt; 10 packyear smoke history ( Number pack years= [ number cigarette per day ÷ 20 ] x number year smoke [ e.g. , 10 packyears equal 20 cigarette per day 10 year , 10 cigarette per day 20 year ] ) . Males females pregnant plan pregnancy study lactate Capable give sign informed consent include compliance requirement restriction list informed consent form ( ICF ) protocol . Exclusion Criteria Subjects current diagnosis asthma . Subjects prior history asthma eligible current diagnosis COPD . Subjects use ELLIPTA inhaler ( participated clinical study GW685698 , GW642444 , GSK573719 [ fluticasone furoate , vilanterol , umeclidinium bromide ] , combination thereof , placebo ELLIPTA inhaler study ) within 24 month prior Visit 0 . Subjects use capsule system inhaler ( e.g . Spiriva HANDIHALER , SEEBRI®/ULTIBRO® BREEZHALER® , participate clinical study , include placebo inhaler ) within 24 month prior Visit 0 . SEEBRI , ULTIBRO , BREEZHALER register trademark Novartis AG . Dependent substudy subject include recent experience , within 24 month V 0 follow inhaler sub study include : Sub Study 1 : DISKUS inhaler ( e.g. , Seretide DISKUS placebo DISKUS ) Sub Study 2 : TURBUHALER ( e.g . Symbicort TURBUHALER placebo TURBUHALER ) Subjects know suspected alcohol drug abuse Visit 1 opinion investigator could interfere subject 's proper completion protocol requirement A history hypersensitivity component study inhaler ( e.g. , lactose , magnesium stearate ) . In addition , subject history severe milk protein allergy , opinion study physician , contraindicate participation also exclude . Subjects receive investigational drug and/or medical device within 30 day entry study ( Screening/Visit 1 ) , within five drug halflives investigational drug , whichever longer In opinion investigator , subject unable read and/or would able complete questionnaire understand verbal instruction .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HANDIHALER</keyword>
	<keyword>ELLIPTA</keyword>
	<keyword>TURBUHALER</keyword>
	<keyword>DISKUS</keyword>
	<keyword>COPD</keyword>
	<keyword>critical error</keyword>
	<keyword>inhaler preference</keyword>
</DOC>